Literature DB >> 8012724

Comparison of the haemodynamic profiles of elgodipine and nicardipine in the anaesthetized dog.

C D Drieu la Rochelle1, A Grosset, S E O'Connor.   

Abstract

1. The haemodynamic profile of elgodipine (1-30 micrograms kg-1, i.v.), a new dihydropyridine calcium antagonist, has been compared directly with that of nicardipine (1-30 micrograms kg-1, i.v.) in chloralose-anaesthetized dogs. 2. Nicardipine produced dose-related systemic, pulmonary and coronary vasodilatation accompanied by reflex tachycardia, inotropy and increases in cardiac output and myocardial oxygen consumption (MVO2). Elgodipine had similar vasodilator and hypotensive properties to nicardipine but produced less reflex inotropy, little or no reflex tachycardia and did not increase MVO2. 3. Both calcium antagonists were retested in a separate group of anaesthetized dogs pretreated with propranolol (1 mg kg-1, i.v.) and atropine (0.3 mg kg-1, i.v.) to abolish reflex autonomic tone to the heart and thus reveal the direct cardiac effects of each compound. Under these conditions both elgodipine and nicardipine decreased heart rate and cardiac contractility and slowed atrio-ventricular conduction. Elgodipine was approximately ten times more potent than nicardipine as a decelerator agent and slightly more potent in depressing cardiac contractility and increasing PR interval duration. Elgodipine, unlike nicardipine, slightly reduced the QTc interval of the electrocardiogram. Therefore, the potent decelerator effect of elgodipine, which was present throughout the dose-range, appears to be largely responsible for the suppression of reflex tachycardia observed when the baroreflex is functional. 4. Elgodipine is a potent systemic and coronary vasodilator with more marked direct cardiac effects than nicardipine, particularly with respect to slowing of heart rate. The ability of elgodipine to increase coronary blood flow without significant reflex tachycardia or increases in MVO2 suggests that this compound will have a more favourable effect on myocardial oxygen supply/demand balance than nicardipine. The haemodynamic profile of elgodipine may be suitable for the treatment of angina.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8012724      PMCID: PMC1910011          DOI: 10.1111/j.1476-5381.1994.tb14022.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Coronary vasodilatory action of elgodipine in coronary artery disease.

Authors:  H Suryapranata; A Maas; D C MacLeod; P J de Feyter; P D Verdouw; P W Serruys
Journal:  Am J Cardiol       Date:  1992-05-01       Impact factor: 2.778

2.  Proischemic complications of dihydropyridine calcium channel blockers.

Authors:  D Waters
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

3.  Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors?

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1989-11-01       Impact factor: 24.094

4.  Cardiovascular effects of elgodipine in conscious pigs with a normal coronary circulation and in conscious pigs with a healed myocardial infarction.

Authors:  L J van Woerkens; S N Schotman; W J van der Giessen; P D Verdouw
Journal:  J Cardiovasc Pharmacol       Date:  1991-06       Impact factor: 3.105

5.  Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting.

Authors:  G A Rooke; E O Feigl
Journal:  Circ Res       Date:  1982-02       Impact factor: 17.367

6.  Cardiovascular effects of the new dihydropyridine derivative elgodipine.

Authors:  J Tamargo; J López-Sendón; E Delpón; M González-Morales; E de Miguel
Journal:  Arzneimittelforschung       Date:  1991-09

7.  Comparison of the cardiovascular actions of N,N-di-n-propyl dopamine and sodium nitroprusside in conscious and chloralose-anaesthetised dogs.

Authors:  S E O'Connor; G W Smith; R A Brown
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

8.  The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs.

Authors:  L M Sassen; L K Soei; M M Koning; P D Verdouw
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

9.  Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells.

Authors:  N Hagiwara; H Irisawa; M Kameyama
Journal:  J Physiol       Date:  1988-01       Impact factor: 5.182

10.  Cardiovascular profile of FPL 62129, a novel dihydropyridine calcium channel blocker, in anaesthetised dogs: a comparison with nifedipine.

Authors:  R G Humphries; S E O'Connor
Journal:  J Cardiovasc Pharmacol       Date:  1988-03       Impact factor: 3.105

View more
  1 in total

1.  Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters.

Authors:  B Silke; S de la Motte; P Spiers; N A Herity; M Drake; J Kelly; F J Harrison
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.